Since novel anti‐HER2 ADC DS‐8201a showed dramatic activity in HER2‐positive and HER2‐low breast cancers,41, 42 further studies of the new‐generation anti‐HER2 ADC in the HER2‐mutant population are warranted. This evidence concerns the gene ERBB2 and breast cancer.